Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Mike WenzelLuigi NoceraClaudia Collà RuvoloChristoph WürnschimmelZhe TianShahrokh F ShariatFred SaadDerya TilkiMarkus GraefenLuis A KluthAlberto BrigantiPhilipp MandelFrancesco MontorsiFelix K H ChunPierre I KarakiewiczPublished in: Prostate cancer and prostatic diseases (2023)